<DOC>
	<DOCNO>NCT02625207</DOCNO>
	<brief_summary>This open-label , parallel group , multiple dose study approximately 48 healthy male female subject African American Caucasian self-reported race , assess effect CYP3A5 genotype PK MVC CYP3A5-derived metabolite . Maraviroc CYP3A5-derived metabolite PK also compare African-Americans Caucasians subject carry two copy dysfunctional CYP3A5 allele ( *3 , *6 , and/or *7 ) .</brief_summary>
	<brief_title>THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC</brief_title>
	<detailed_description>This open-label , parallel group , multiple dose study approximately 48 healthy male female subject African American Caucasian self-reported race , assess effect CYP3A5 genotype PK MVC CYP3A5-derived metabolite . Maraviroc CYP3A5-derived metabolite PK also compare African-Americans Caucasians subject carry two copy dysfunctional CYP3A5 allele ( *3 , *6 , and/or *7 ) . Dysfunctional genetic variant CYP3A5 , CYP3A4 SLCO1B1 genotyped subject participate pre-screening . Subjects meet inclusion/exclusion criterion study participation place study cohort base race number functional ( *1 ) dysfunctional CYP3A5 allele ( *3 , *6 , *7 ) CYP3A5 allele . Cohort 1 ( n=12 ; African-American ) : No CYP3A5*1 allele ( poor metabolizer ) . Cohort 2 ( n=12 ; African-American ) : One CYP3A5*1 allele ( intermediate metabolizer ) . Cohort 3 ( n=12 ; African-American ) : Two CYP3A5*1 allele ( extensive metabolizer ) . Cohort 4 ( n=12 ; Caucasian ) : No CYP3A5*1 allele ( poor metabolizer ) . Study Treatments : Part 1 Days 1-5 : Maraviroc 300 mg BID fast state ( AM dose Day 5 ) . Part 2 ( Cohorts 1 3 ) Days 1-10 : Maraviroc 150 mg QD plus darunavir/cobicistat 800/150 mg QD food . Pharmacokinetics MVC , PF-6857639 , PF-6857640 hydroxylated metabolite formation mediate CYP3A5 ( present ) assess Part 1 , Day 5 Part 2 , Days 10-11 . Blood sample collect full PK profile . Subjects confine Clinical Research Unit ( CRU ) day prior dose Day 1 ( Day 0 ) discharge Part 1 , Day 6 Part 2 , Day 11 ( Cohorts 1 3 ) . Subjects enrol Cohorts 1 3 may confine CRU without need discharge Part 1 Part 2 .</detailed_description>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) Healthy female subject and/or male subject AfricanAmerican/Black Caucasian race History regular alcohol consumption exceed 7 drinks/week female 14 drinks/week male Treatment investigational drug within 30 day Screening supine blood pressure &lt; 90 &gt; /=140 mm Hg ( systolic ) &lt; 60 &gt; /= 90 mm Hg ( diastolic ) , follow least 5 minute supine rest Use prescription nonprescription drug dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose study medication . Use tobacco nicotinecontaining product excess equivalent 5 cigarette per day Subjects CYP3A4*22 allele and/or SLCO1B1 *5 *15 allele</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Maraviroc , CYP3A5 , pharmacokinetics , pharmacogenomics</keyword>
</DOC>